Full‐mouth disinfection as a therapeutic protocol for type‐2 diabetic subjects with chronic periodontitis: Twelve‐month clinical outcomes. A randomized controlled clinical trial

Abstract

The treatments did not differ with respect to clinical parameters, including the primary outcome variable (i.e. changes in clinical attachment level in deep pockets), for up to 12 months post-treatments.

Routine Prophylaxes Every 3 Months Improves Chronic Periodontitis Status in Type 2 Diabetes

“…In the da Cruz et al 30 study, patients with well‐controlled and poorly controlled DM were pooled, and the mean 9.23% ± 2.60% of HbA1c levels at baseline showed a slight increase to 9.4% ± 2.53% 3 months after full‐mouth SRP. A randomized controlled clinical trial 36 that used chlorhexidine in a full‐mouth disinfection protocol in patients with poorly controlled DM (HbA1c 10.0% ± 2.4% at baseline) did not find significant improvement of glycemic levels for up to 12 months post‐treatment. Thus, in several studies, the results of the effects of periodontal treatment on HbA1c levels appear to be independent of the pretreatment level of glycemic control.…”

Clinical and Microbiologic Evaluation of Scaling and Root Planing per Quadrant and One‐Stage Full‐Mouth Disinfection Associated With Azithromycin or Chlorhexidine: A Clinical Randomized Controlled Trial

“…On the other hand, a randomized clinical trial comparing FDM with and without CHX showed no differences in the periodontal clinical parameters PD and CAL at 3, 6, and 12 months after treatment 43 . In addition, a recent systematic review and meta‐analysis designed to evaluate the clinical effect of FMD compared with QS showed no benefit of FMD over QS for changes in PD and gain in CAL.…”

Metronidazole and amoxicillin as adjuncts to scaling and root planing for the treatment of type 2 diabetic subjects with periodontitis: 1‐year outcomes of a randomized placebo‐controlled clinical trial

“…, Santos et al. ). Doxycycline at antimicrobial and sub‐antimicrobial doses has been long the most evaluated medication as adjunct to SRP for treatment of diabetic subjects (Grossi et al.…”